There appears to be a deficit in endogenous INF-β-regulated T cell homeostasis in some people with RRMS which is corrected by INF-β therapy via the upregulation of suppressor of cytokine signalling 3 (SOCS3) [130]. The gene discussed is SOCS3; the disease is relapsing-remitting multiple sclerosis.